News

BUILT Biotechnologies Named Commonwealth BioAccelerator Anchor Company As Emerging Leader in DNA Manufacturing-as-Service Scales to Meet Exploding Demand

BUILT Biotechnologies, an emerging leader in DNA Manufacturing-as-a-Service, today announced its selection as an anchor company at the Commonwealth BioAccelerator, an initiative led by CvilleBioHub to strengthen Virginia’s biotechnology ecosystem. The relocation of BUILT’s headquarters to CvilleBioHub’s state-of-the-art facilities at North Fork Research Park positions the company to rapidly scale production in a new, next-generation laboratory to meet exploding demand and to grow its team by tapping Charlottesville’s talent pool.

Through its breakthrough Regenerative DNA Assembly™ process, BUILT is bridging the gap between DNA synthesis and ready-to-use DNA molecules for a growing roster of customers nationwide, from top-10 biopharma companies to university core facilities to small startups, enabling them to accelerate programs in cell and gene therapy, RNA therapeutics, and synthetic biology broadly.

The company routinely ships BUILT DNA™: sequence-perfect DNA constructs, including “unbuildable” long and complex molecules, in linear and plasmid formats. BUILT’s service provides biotech innovators with unparalleled capability, reliability, and speed, eliminating the need for in-house assembly and stepping up development timelines.

George McArthur, PhD, CEO of BUILT Biotechnologies, stated, “Our designation as an anchor company at the Commonwealth BioAccelerator validates BUILT’s rapid emergence as the partner of choice for the full range of life science operations seeking a more efficient and cost-effective way to access highest-quality, ready-built DNA. Our new North Fork lab will provide the capacity to scale and meet this pressing market need, as well as to recruit exceptional local talent and partner more closely with CvilleBioHub.”

With its expanded presence at North Fork, BUILT is also positioned to collaborate with the new Paul and Diane Manning Institute of Biotechnology at the University of Virginia, underscoring the company’s ability to serve innovators both globally and locally.

“BUILT exemplifies the kind of scale-ready company we’re proud to champion in Central Virginia,” said Nikki Hastings, PhD, Executive Director of CvilleBioHub. “As an anchor company of the Commonwealth BioAccelerator, BUILT strengthens our ecosystem by delivering the reliable, fast, and capable DNA manufacturing that growing therapeutics companies need to move from idea to impact.” The Commonwealth BioAccelerator, operated by CvilleBioHub and supported by public and private partners, provides companies with the resources and community to scale in Virginia’s biotech ecosystem.

Recent News

02/25/2026

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals Inc., a clinical-stage biopharmaceutical company dedicated to treating MASH, obesity, and associated cardiometabolic diseases, today announced the appointment of Jorge Bartolome as Chief Executive Officer and member of the Board. He succeeds Allen Cunningham, a co-founder who will move to the role of Chief Operating Officer. Mr. Bartolome has over 25 years of

02/24/2026

Jeeva Clinical Trials Calls on Global Life Sciences Leaders to Modernize Infrastructure for AI-Driven Drug Development

Jeeva Clinical Trials today amplified its call to action for the global pharmaceutical and clinical research ecosystem: Artificial Intelligence will not transform drug development unless organizations modernize the IT infrastructure beneath it. The message — first articulated in a recent thought leadership article by Founder and CEO Harsha K. Rajasimha — has gained strong traction

02/24/2026

Liquet™ Medical Receives Second FDA 510(k) Clearance for Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received a second 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new configuration of the Versus™ Catheter. The latest clearance expands the company’s proprietary platform and opens access to a broader